Literature DB >> 24578278

MR quantitative susceptibility imaging for the evaluation of iron loading in the brains of patients with β-thalassemia major.

D Qiu1, G C-F Chan2, J Chu3, Q Chan4, S-Y Ha2, M E Moseley5, P-L Khong6.   

Abstract

BACKGROUND AND
PURPOSE: Patients with β-thalassemia require blood transfusion to prolong their survival, which could cause iron overload in multiple organs, including the heart, liver, and brain. In this study, we aimed to quantify iron loading in the brains of patients with β-thalassemia major through the use of MR quantitative susceptibility imaging.
MATERIALS AND METHODS: Thirty-one patients with thalassemia with a mean (± standard deviation) age of 25.3 (±5.9) years and 33 age-matched healthy volunteers were recruited and underwent MR imaging at 3T. Quantitative susceptibility images were reconstructed from a 3D gradient-echo sequence. Susceptibility values were measured in the caudate nucleus, putamen, globus pallidus, red nucleus, substantia nigra, dentate nucleus, and choroid plexus. General linear model analyses were performed to compare susceptibility values of different ROIs between the patients with thalassemia and healthy volunteers.
RESULTS: Of the 31 patients, 27 (87.1%) had abnormal iron deposition in one of the ROIs examined. Significant positive age effect on susceptibility value was found in the putamen, dentate nucleus, substantia nigra, and red nucleus (P = .002, P = .017, P = .044, and P = .014, respectively) in the control subjects. Compared with healthy control subjects, patients with thalassemia showed significantly lower susceptibility value in the globus pallidus (P < .001) and substantia nigra (P = .003) and significantly higher susceptibility value in the red nucleus (P = .021) and choroid plexus (P < .001).
CONCLUSIONS: A wide range of abnormal susceptibility values, indicating iron overloading or low iron content, was found in patients with thalassemia. MR susceptibility imaging is a sensitive method for quantifying iron concentration in the brain and can be used as a potentially valuable tool for brain iron assessment.
© 2014 by American Journal of Neuroradiology.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24578278      PMCID: PMC7965158          DOI: 10.3174/ajnr.A3849

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   3.825


  26 in total

1.  T(2) relaxation rate of basal ganglia and cortex in patients with beta-thalassaemia major.

Authors:  Z Metafratzi; M I Argyropoulou; D N Kiortsis; C Tsampoulas; N Chaliassos; S C Efremidis
Journal:  Br J Radiol       Date:  2001-05       Impact factor: 3.039

2.  Whole-brain susceptibility mapping at high field: a comparison of multiple- and single-orientation methods.

Authors:  Sam Wharton; Richard Bowtell
Journal:  Neuroimage       Date:  2010-07-06       Impact factor: 6.556

Review 3.  Beta-thalassemia.

Authors:  Deborah Rund; Eliezer Rachmilewitz
Journal:  N Engl J Med       Date:  2005-09-15       Impact factor: 91.245

Review 4.  Magnetic resonance imaging of iron deposition in neurological disorders.

Authors:  Steven D Brass; Nan-kuei Chen; Robert V Mulkern; Rohit Bakshi
Journal:  Top Magn Reson Imaging       Date:  2006-02

5.  Neurophysiologic and intellectual evaluation of beta-thalassemia patients.

Authors:  Marina Economou; Dimitrios I Zafeiriou; Eleftherios Kontopoulos; Nikos Gompakis; Aphroditi Koussi; Vasilios Perifanis; Miranda Athanassiou-Metaxa
Journal:  Brain Dev       Date:  2005-05-31       Impact factor: 1.961

Review 6.  Deferiprone for the treatment of Friedreich's ataxia.

Authors:  Massimo Pandolfo; Laura Hausmann
Journal:  J Neurochem       Date:  2013-08       Impact factor: 5.372

Review 7.  Iron-chelating therapy and the treatment of thalassemia.

Authors:  N F Olivieri; G M Brittenham
Journal:  Blood       Date:  1997-02-01       Impact factor: 22.113

8.  Magnetic susceptibility mapping of brain tissue in vivo using MRI phase data.

Authors:  Karin Shmueli; Jacco A de Zwart; Peter van Gelderen; Tie-Qiang Li; Stephen J Dodd; Jeff H Duyn
Journal:  Magn Reson Med       Date:  2009-12       Impact factor: 4.668

9.  Human brain atlas for automated region of interest selection in quantitative susceptibility mapping: application to determine iron content in deep gray matter structures.

Authors:  Issel Anne L Lim; Andreia V Faria; Xu Li; Johnny T C Hsu; Raag D Airan; Susumu Mori; Peter C M van Zijl
Journal:  Neuroimage       Date:  2013-06-12       Impact factor: 6.556

10.  Differential developmental trajectories of magnetic susceptibility in human brain gray and white matter over the lifespan.

Authors:  Wei Li; Bing Wu; Anastasia Batrachenko; Vivian Bancroft-Wu; Rajendra A Morey; Vandana Shashi; Christian Langkammer; Michael D De Bellis; Stefan Ropele; Allen W Song; Chunlei Liu
Journal:  Hum Brain Mapp       Date:  2013-09-13       Impact factor: 5.038

View more
  12 in total

Review 1.  Susceptibility-weighted imaging and quantitative susceptibility mapping in the brain.

Authors:  Chunlei Liu; Wei Li; Karen A Tong; Kristen W Yeom; Samuel Kuzminski
Journal:  J Magn Reson Imaging       Date:  2014-10-01       Impact factor: 4.813

2.  Dentate nucleus T1 hyperintensity: is it always gadolinium all that glitters?

Authors:  Luca Pasquini; Maria Camilla Rossi Espagnet; Antonio Napolitano; Daniela Longo; Alice Bertaina; Emiliano Visconti; Paolo Tomà
Journal:  Radiol Med       Date:  2018-01-27       Impact factor: 3.469

3.  Brain-derived neurotrophic factor plasma levels and premature cognitive impairment/dementia in type 2 diabetes.

Authors:  Blanca Murillo Ortíz; Joel Ramírez Emiliano; Edna Ramos-Rodríguez; Sandra Martínez-Garza; Hilda Macías-Cervantes; Sergio Solorio-Meza; Texar Alfonso Pereyra-Nobara
Journal:  World J Diabetes       Date:  2016-12-15

Review 4.  The Efficacy of Iron Chelators for Removing Iron from Specific Brain Regions and the Pituitary-Ironing out the Brain.

Authors:  Robert R Crichton; Roberta J Ward; Robert C Hider
Journal:  Pharmaceuticals (Basel)       Date:  2019-09-17

5.  Brain Iron Deposits in Thalamus Is an Independent Factor for Depressive Symptoms Based on Quantitative Susceptibility Mapping in an Older Adults Community Population.

Authors:  Wenhua Zhang; Ying Zhou; Qingqing Li; Jinjin Xu; Shenqiang Yan; Jinsong Cai; Yeerfan Jiaerken; Min Lou
Journal:  Front Psychiatry       Date:  2019-10-15       Impact factor: 4.157

6.  Middle cerebral artery thrombus susceptibility-weighted imaging mapping predicts prognosis.

Authors:  Mei-Zhu Zheng; Qing-Yuan Yang; Xiu-Di Lu; Si-Le Hu; Chao Chai; Wen Shen; Bin-Ge Chang; Zhi-Yun Wang; Shuang Xia
Journal:  Quant Imaging Med Surg       Date:  2019-09

7.  Early-Life Iron Deficiency Reduces Brain Iron Content and Alters Brain Tissue Composition Despite Iron Repletion: A Neuroimaging Assessment.

Authors:  Austin T Mudd; Joanne E Fil; Laura C Knight; Fan Lam; Zhi-Pei Liang; Ryan N Dilger
Journal:  Nutrients       Date:  2018-01-27       Impact factor: 5.717

8.  Brain iron content in systemic iron overload: A beta-thalassemia quantitative MRI study.

Authors:  Renzo Manara; Sara Ponticorvo; Immacolata Tartaglione; Gianluca Femina; Andrea Elefante; Camilla Russo; Pasquale Alessandro Carafa; Mario Cirillo; Maddalena Casale; Angela Ciancio; Rosanna Di Concilio; Elisa De Michele; Nikolaus Weiskopf; Francesco Di Salle; Silverio Perrotta; Fabrizio Esposito
Journal:  Neuroimage Clin       Date:  2019-10-25       Impact factor: 4.881

9.  Iron accumulation in the choroid plexus, ependymal cells and CNS parenchyma in a rat strain with low-grade haemolysis of fragile macrocytic red blood cells.

Authors:  Isabella Wimmer; Cornelia Scharler; Taro Kadowaki; Sophie Hillebrand; Barbara Scheiber-Mojdehkar; Shuichi Ueda; Monika Bradl; Thomas Berger; Hans Lassmann; Simon Hametner
Journal:  Brain Pathol       Date:  2021-01-29       Impact factor: 6.508

10.  Neuroimaging Findings in Pediatric Patients with Thalassemia Major.

Authors:  Yılmaz Akbaş; Sultan Aydın; Gökçen Öz Tunçer; Alper Köker; Yasemin Çoban; Gönül Oktay; Hakan Yeral
Journal:  Hematol Rep       Date:  2022-03-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.